Potentia Pharmaceuticals, Inc. has entered into an exclusive, worldwide licensing agreement with the University of Pennsylvania that provides broad rights to develop and commercialize University of Pennsylvania's Compstatin class of complement-inhibiting peptides for the treatment of ocular diseases.
The said agreement will allow Potentia to move forward with the preclinical development of the first complement-inhibiting drug product aimed at treating both the "wet" and "dry" forms of age-related macular degeneration (ARMD).
"We are excited to work with the University of Pennsylvania in developing the first treatment for macular degeneration based on the important genetic findings of the last year," said Cedric Francois, M.D., Ph.D., Chief Executive Officer for Potentia.
"Genetic analysis of patients with macular degeneration has now clearly established that excessive complement activation is involved in the development of macular degeneration. Compstatin is one of the best complement-inhibiting drugs available and we look forward to evaluating its potential and to helping patients suffering from this devastating disease."
The terms of the agreement were not disclosed.
More details at the full press release.
Comment Preview